Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Judit Morello

Showing results (21-30 of 52) with videos related to

Pageof 6
Sort By:
AIDS (London, England)|February 20, 2010
Safety and efficacy of tenofovir/emtricitabine plus nevirapine in HIV-infected patientsPablo Labarga, Jose Medrano, Eduardo Seclen, et al.
Antiviral Therapy|August 5, 2008
Distinct hepatitis C virus kinetics in HIV-infected patients treated with ribavirin plus either pegylated interferon alpha2a or alpha2bEugenia Vispo, Pablo Barreiro, Sonia Rodriguez-Nóvoa, et al.
Free Radical Biology & Medicine|October 21, 2018
The first-line antiepileptic drug carbamazepine: Reaction with biologically relevant free radicalsInês L Martins, João Nunes, Catarina Charneira, et al.
The Journal of Infectious Diseases|September 4, 2010
Influence of a single nucleotide polymorphism at the main ribavirin transporter gene on the rapid virological response to pegylated interferon-ribavirin therapy in patients with chronic hepatitis C virus infectionJudit Morello, Lorena Cuenca, Vincent Soriano, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|January 27, 2010
Rate and predictors of success in the retreatment of chronic hepatitis C virus in HIV/hepatitis C Virus coinfected patients with prior nonresponse or relapsePablo Labarga, Eugenia Vispo, Pablo Barreiro, et al.
AIDS (London, England)|November 14, 2008
Increase in serum bilirubin in HIV/hepatitis-C virus-coinfected patients on atazanavir therapy following initiation of pegylated-interferon and ribavirinSonia Rodríguez-Nóvoa, Judit Morello, Mar González, et al.
Antimicrobial Agents and Chemotherapy|January 27, 2010
Plasma ribavirin trough concentrations at week 4 predict hepatitis C virus (HCV) relapse in HIV-HCV-coinfected patients treated for chronic hepatitis CJudit Morello, Vincent Soriano, Pablo Barreiro, et al.
Pharmacological Research|January 8, 2021
AHR canonical pathway: in vivo findings to support novel antihypertensive strategiesNuno R Coelho, Clara Matos, António B Pimpão, et al.
AIDS Research and Human Retroviruses|April 5, 2011
Plasma raltegravir exposure influences the antiviral activity and selection of resistance mutationsCarolina Garrido, Carmen de Mendoza, Elena Alvarez, et al.
Therapeutic Drug Monitoring|March 11, 2010
The benefit of simplification from tipranavir/ritonavir 500/200 bid to 500/100 bid guided by therapeutic drug monitoringJudit Morello, Sonia Rodríguez-Novoa, Francisco Blanco, et al.
Pageof 6

Showing results (21-30 of 52) with videos related to

Sort By:
Pageof 6
AIDS (London, England)|February 20, 2010
Safety and efficacy of tenofovir/emtricitabine plus nevirapine in HIV-infected patientsPablo Labarga, Jose Medrano, Eduardo Seclen, et al.
Antiviral Therapy|August 5, 2008
Distinct hepatitis C virus kinetics in HIV-infected patients treated with ribavirin plus either pegylated interferon alpha2a or alpha2bEugenia Vispo, Pablo Barreiro, Sonia Rodriguez-Nóvoa, et al.
Free Radical Biology & Medicine|October 21, 2018
The first-line antiepileptic drug carbamazepine: Reaction with biologically relevant free radicalsInês L Martins, João Nunes, Catarina Charneira, et al.
The Journal of Infectious Diseases|September 4, 2010
Influence of a single nucleotide polymorphism at the main ribavirin transporter gene on the rapid virological response to pegylated interferon-ribavirin therapy in patients with chronic hepatitis C virus infectionJudit Morello, Lorena Cuenca, Vincent Soriano, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|January 27, 2010
Rate and predictors of success in the retreatment of chronic hepatitis C virus in HIV/hepatitis C Virus coinfected patients with prior nonresponse or relapsePablo Labarga, Eugenia Vispo, Pablo Barreiro, et al.
AIDS (London, England)|November 14, 2008
Increase in serum bilirubin in HIV/hepatitis-C virus-coinfected patients on atazanavir therapy following initiation of pegylated-interferon and ribavirinSonia Rodríguez-Nóvoa, Judit Morello, Mar González, et al.
Antimicrobial Agents and Chemotherapy|January 27, 2010
Plasma ribavirin trough concentrations at week 4 predict hepatitis C virus (HCV) relapse in HIV-HCV-coinfected patients treated for chronic hepatitis CJudit Morello, Vincent Soriano, Pablo Barreiro, et al.
Pharmacological Research|January 8, 2021
AHR canonical pathway: in vivo findings to support novel antihypertensive strategiesNuno R Coelho, Clara Matos, António B Pimpão, et al.
AIDS Research and Human Retroviruses|April 5, 2011
Plasma raltegravir exposure influences the antiviral activity and selection of resistance mutationsCarolina Garrido, Carmen de Mendoza, Elena Alvarez, et al.
Therapeutic Drug Monitoring|March 11, 2010
The benefit of simplification from tipranavir/ritonavir 500/200 bid to 500/100 bid guided by therapeutic drug monitoringJudit Morello, Sonia Rodríguez-Novoa, Francisco Blanco, et al.
Pageof 6